Brief: Clearside Biomedical Says Suprachoroidal Injection Of CLS-AX Resulted In Favorable Safety Data, Durability, Biologic Effect Over 6 Months
31/07/2023 12:32
July 31 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL INC - SUPRACHOROIDAL INJECTION OF
CLS-AX
RESULTED IN FAVORABLE SAFETY DATA, DURABILITY AND BIOLOGIC
EFFECT OVER 6 MONTHS
Source text for Eikon: ID:nGNX1nVG0R
Further company coverage: CLSD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials